Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000029.xml
Download PDF
J Reconstr Microsurg 2022; 38(08): 621-629
DOI: 10.1055/s-0042-1742731
DOI: 10.1055/s-0042-1742731
Original Article
Noninvasive Systemic Modalities for Prevention of Head and Neck Radiation-Associated Soft Tissue Injury: A Narrative Review
Funding/Acknowledgments This research was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. Babak Mehrara is a consultant for PureTech Corporation and receives research funding from Regeneron. The rest of the authors have no conflicts of interest, financial or otherwise, to report.
Abstract
Background Radiation-associated soft tissue injury is a potentially devastating complication for head and neck cancer patients. The damage can range from minor sequelae such as xerostomia, which requires frequent daily maintenance, to destructive degenerative processes such as osteoradionecrosis, which can contribute to flap failure and delay or reverse oral rehabilitation. Despite the need for effective radioprotectants, the literature remains sparse, primarily focused on interventions beyond the surgeon's control, such as maintenance of good oral hygiene or modulation of radiation dose.
Methods This narrative review aggregates and explores noninvasive, systemic treatment modalities for prevention or amelioration of radiation-associated soft tissue injury.
Results We highlighted nine modalities with the most clinical potential, which include amifostine, melatonin, palifermin, hyperbaric oxygen therapy, photobiomodulation, pentoxifylline–tocopherol–clodronate, pravastatin, transforming growth factor-β modulators, and deferoxamine, and reviewed the benefits and limitations of each modality. Unfortunately, none of these modalities are supported by strong evidence for prophylaxis against radiation-associated soft tissue injury.
Conclusion While we cannot endorse any of these nine modalities for immediate clinical use, they may prove fruitful areas for further investigation.
Publication History
Received: 15 September 2021
Accepted: 27 December 2021
Article published online:
25 February 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Weintraub NL, Jones WK, Manka D. Understanding radiation-induced vascular disease. J Am Coll Cardiol 2010; 55 (12) 1237-1239
- 2 FitzGerald TJ, Bishop-Jodoin M, Laurie F, Lukez A, O'Loughlin L, Sacher A. Treatment toxicity: radiation. Hematol Oncol Clin North Am 2019; 33 (06) 1027-1039
- 3 Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004; 26 (09) 796-807
- 4 Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist 2008; 13 (08) 886-898
- 5 Bonzanini LIL, Soldera EB, Ortigara GB. et al. Clinical and sociodemographic factors that affect the quality of life of survivors of head and neck cancer. Support Care Cancer 2020; 28 (04) 1941-1950
- 6 Brook I. Late side effects of radiation treatment for head and neck cancer. Radiat Oncol J 2020; 38 (02) 84-92
- 7 Halle M, Gabrielsen A, Paulsson-Berne G. et al. Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries. J Am Coll Cardiol 2010; 55 (12) 1227-1236
- 8 Tian X, Xu L, Liu X. et al. Impact of honey on radiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. Ann Palliat Med 2020; 9 (04) 1431-1441
- 9 Bamba R, Shadfar S, Van Natta BW. Fat grafting as a novel treatment for xerostomia. J Craniofac Surg 2021; 32 (02) e211-e215
- 10 Griffin MF, Drago J, Almadori A, Kalavrezos N, Butler PE. Evaluation of the efficacy of lipotransfer to manage radiation-induced fibrosis and volume defects in head and neck oncology. Head Neck 2019; 41 (10) 3647-3655
- 11 Ge X, Liao Z, Yuan J. et al. Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis. Support Care Cancer 2020; 28 (06) 2701-2712
- 12 Siddiqui F, Movsas B. Management of radiation toxicity in head and neck cancers. Semin Radiat Oncol 2017; 27 (04) 340-349
- 13 Riley P, Glenny AM, Hua F, Worthington HV. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database Syst Rev 2017; 7 (07) CD012744
- 14 El-Rabbany M, Duchnay M, Raziee HR. et al. Interventions for preventing osteoradionecrosis of the jaws in adults receiving head and neck radiotherapy. Cochrane Database Syst Rev 2019; 2019 (11) CD011559
- 15 Scrimger R. Salivary gland sparing in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2011; 11 (09) 1437-1448
- 16 Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007; 12 (06) 738-747
- 17 Gu J, Zhu S, Li X, Wu H, Li Y, Hua F. Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials. PLoS One 2014; 9 (05) e95968
- 18 Lee MG, Freeman AR, Roos DE, Milner AD, Borg MF. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer. J Med Imaging Radiat Oncol 2019; 63 (01) 142-150
- 19 Porter SR, Fedele S, Habbab KM. Xerostomia in head and neck malignancy. Oral Oncol 2010; 46 (06) 460-463
- 20 Quock RL. Xerostomia: current streams of investigation. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 122 (01) 53-60
- 21 Ranganathan K, Simon E, Lynn J. et al. Novel formulation strategy to improve the feasibility of amifostine administration. Pharm Res 2018; 35 (05) 99
- 22 Aarup-Kristensen S, Hansen CR, Forner L, Brink C, Eriksen JG, Johansen J. Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations. Acta Oncol 2019; 58 (10) 1373-1377
- 23 Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14 (03) 199-212
- 24 King M, Joseph S, Albert A. et al. Use of amifostine for cytoprotection during radiation therapy: a review. Oncology 2020; 98 (02) 61-80
- 25 Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 2004; 70 (03) 261-264
- 26 Vijayalaxmi, Reiter RJ, Tan DX, Herman TS, Thomas Jr CR. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 2004; 59 (03) 639-653
- 27 Shirazi A, Ghobadi G, Ghazi-Khansari M. A radiobiological review on melatonin: a novel radioprotector. J Radiat Res (Tokyo) 2007; 48 (04) 263-272
- 28 Elsabagh HH, Moussa E, Mahmoud SA, Elsaka RO, Abdelrahman H. Efficacy of melatonin in prevention of radiation-induced oral mucositis: a randomized clinical trial. Oral Dis 2020; 26 (03) 566-572
- 29 Lozano A, Marruecos J, Rubió J. et al. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clin Transl Oncol 2021; 23 (09) 1801-1810
- 30 Ben-David MA, Elkayam R, Gelernter I, Pfeffer RM. Melatonin for prevention of breast radiation dermatitis: a phase II, prospective, double-blind randomized trial. Isr Med Assoc J 2016; 18 (3–4): 188-192
- 31 McDonnell AM, Lenz KL. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. Ann Pharmacother 2007; 41 (01) 86-94
- 32 Sadeghi S, Kalhor H, Panahi M. et al. Keratinocyte growth factor in focus: a comprehensive review from structural and functional aspects to therapeutic applications of palifermin. Int J Biol Macromol 2021; 191: 1175-1190
- 33 Swedish Orphan Biovitrum AB. Kepivance (palifermin) [package insert]. US Food and Drug Administration. Revised December 2019. Accessed February 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125103s171s172lbl.pdf
- 34 Blakaj A, Bonomi M, Gamez ME, Blakaj DM. Oral mucositis in head and neck cancer: evidence-based management and review of clinical trial data. Oral Oncol 2019; 95: 29-34
- 35 Henke M, Alfonsi M, Foa P. et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011; 29 (20) 2815-2820
- 36 Le QT, Kim HE, Schneider CJ. et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011; 29 (20) 2808-2814
- 37 Nooka AK, Johnson HR, Kaufman JL. et al. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20 (06) 852-857
- 38 Elting LS, Shih YC, Stiff PJ. et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007; 13 (07) 806-813
- 39 Tra WM, Spiegelberg L, Tuk B, Hovius SE, Perez-Amodio S. Hyperbaric oxygen treatment of tissue-engineered mucosa enhances secretion of angiogenic factors in vitro. Tissue Eng Part A 2014; 20 (9–10): 1523-1530
- 40 Svalestad J, Thorsen E, Vaagbø G, Hellem S. Effect of hyperbaric oxygen treatment on oxygen tension and vascular capacity in irradiated skin and mucosa. Int J Oral Maxillofac Surg 2014; 43 (01) 107-112
- 41 Lindenmann J, Smolle C, Kamolz LP, Smolle-Juettner FM, Graier WF. Survey of molecular mechanisms of hyperbaric oxygen in tissue repair. Int J Mol Sci 2021; 22 (21) 11754
- 42 Bennett MH, Feldmeier J, Hampson NB, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev 2016; 4: CD005005
- 43 Ravi P, Vaishnavi D, Gnanam A, Krishnakumar Raja VB. The role of hyperbaric oxygen therapy in the prevention and management of radiation-induced complications of the head and neck - a systematic review of literature. J Stomatol Oral Maxillofac Surg 2017; 118 (06) 359-362
- 44 Sultan A, Hanna GJ, Margalit DN. et al. The use of hyperbaric oxygen for the prevention and management of osteoradionecrosis of the jaw: a Dana-Farber/Brigham and Women's Cancer Center multidisciplinary guideline. Oncologist 2017; 22 (11) 1413
- 45 Shaw RJ, Butterworth CJ, Silcocks P. et al. HOPON (hyperbaric oxygen for the prevention of osteoradionecrosis): a randomized controlled trial of hyperbaric oxygen to prevent osteoradionecrosis of the irradiated mandible after dentoalveolar surgery. Int J Radiat Oncol Biol Phys 2019; 104 (03) 530-539
- 46 Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 2018; 4: CD005007
- 47 Curi MM, Condezo AFB, Ribeiro KDCB, Cardoso CL. Long-term success of dental implants in patients with head and neck cancer after radiation therapy. Int J Oral Maxillofac Surg 2018; 47 (06) 783-788
- 48 Hartford AC, Davis TH, Buckey JC. et al. Hyperbaric oxygen as radiation sensitizer for locally advanced squamous cell carcinoma of the oropharynx: a phase 1 dose-escalation study. Int J Radiat Oncol Biol Phys 2017; 97 (03) 481-486
- 49 Hoggan BL, Cameron AL. Systematic review of hyperbaric oxygen therapy for the treatment of non-neurological soft tissue radiation-related injuries. Support Care Cancer 2014; 22 (06) 1715-1726
- 50 Schoen PJ, Raghoebar GM, Bouma J. et al. Rehabilitation of oral function in head and neck cancer patients after radiotherapy with implant-retained dentures: effects of hyperbaric oxygen therapy. Oral Oncol 2007; 43 (04) 379-388
- 51 Sherlock S, Way M, Tabah A. Hyperbaric oxygen treatment for the management of radiation-induced xerostomia. J Med Imaging Radiat Oncol 2018; 62 (06) 841-846
- 52 Teguh DN, Levendag PC, Noever I. et al. Early hyperbaric oxygen therapy for reducing radiotherapy side effects: early results of a randomized trial in oropharyngeal and nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 2009; 75 (03) 711-716
- 53 Wu Y, Huang W, Zhang Z, Zhang Z, Zou D. Long-term success of dental implant-supported dentures in postirradiated patients treated for neoplasms of the maxillofacial skeleton: a retrospective study. Clin Oral Investig 2016; 20 (09) 2457-2465
- 54 Spiegelberg L, Djasim UM, van Neck HW, Wolvius EB, van der Wal KG. Hyperbaric oxygen therapy in the management of radiation-induced injury in the head and neck region: a review of the literature. J Oral Maxillofac Surg 2010; 68 (08) 1732-1739
- 55 Undersea and Hyperbaric Medicine Society. UHMS Accredited Clinical Hyperbaric Medicine Facilities. Updated January 31, 2021. Accessed February 18, 2021 at: https://www.uhms.org/images/Accredited-Facilities/UHMS_Accredited_Facilities_January_2021.pdf
- 56 Bulsara VM, Bulsara MK, Lewis E. Protocol for prospective randomised assessor-blinded pilot study comparing hyperbaric oxygen therapy with PENtoxifylline+TOcopherol ± CLOdronate for the management of early osteoradionecrosis of the mandible. BMJ Open 2019; 9 (03) e026662
- 57 Fernandez E, Morillo V, Salvador M. et al. Hyperbaric oxygen and radiation therapy: a review. Clin Transl Oncol 2021; 23 (06) 1047-1053
- 58 Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc 1985; 111 (01) 49-54
- 59 Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng 2012; 40 (02) 516-533
- 60 Chen AC, Arany PR, Huang YY. et al. Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One 2011; 6 (07) e22453
- 61 Bensadoun RJ. Photobiomodulation or low-level laser therapy in the management of cancer therapy-induced mucositis, dermatitis and lymphedema. Curr Opin Oncol 2018; 30 (04) 226-232
- 62 Cronshaw M, Parker S, Anagnostaki E, Mylona V, Lynch E, Grootveld M. Photobiomodulation and oral mucositis: a systematic review. Dent J (Basel) 2020; 8 (03) 87
- 63 da Silva TMV, Melo TS, de Alencar RC. et al. Photobiomodulation for mucosal repair in patients submitted to dental extraction after head and neck radiation therapy: a double-blind randomized pilot study. Support Care Cancer 2021; 29 (03) 1347-1354
- 64 Louzeiro GC, Cherubini K, de Figueiredo MAZ, Salum FG. Effect of photobiomodulation on salivary flow and composition, xerostomia and quality of life of patients during head and neck radiotherapy in short term follow-up: a randomized controlled clinical trial. J Photochem Photobiol B 2020; 209: 111933
- 65 Marín-Conde F, Castellanos-Cosano L, Pachón-Ibañez J, Serrera-Figallo MA, Gutiérrez-Pérez JL, Torres-Lagares D. Photobiomodulation with low-level laser therapy reduces oral mucositis caused by head and neck radio-chemotherapy: prospective randomized controlled trial. Int J Oral Maxillofac Surg 2019; 48 (07) 917-923
- 66 Park JH, Byun HJ, Lee JH. et al. Feasibility of photobiomodulation therapy for the prevention of radiodermatitis: a single-institution pilot study. Lasers Med Sci 2020; 35 (05) 1119-1127
- 67 Huang YY, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy - an update. Dose Response 2011; 9 (04) 602-618
- 68 Gautam AP, Fernandes DJ, Vidyasagar MS, Maiya AG, Nigudgi S. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy–a randomized controlled trial. Support Care Cancer 2013; 21 (05) 1421-1428
- 69 Kauark-Fontes E, Migliorati CA, Epstein JB. et al. Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial. Support Care Cancer 2022; 30 (03) 2225-2236
- 70 Bensadoun RJ, Epstein JB, Nair RG. et al; World Association for Laser Therapy (WALT). Safety and efficacy of photobiomodulation therapy in oncology: a systematic review. Cancer Med 2020; 9 (22) 8279-8300
- 71 Genot-Klastersky MT, Paesmans M, Ameye L. et al. Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer. Support Care Cancer 2020; 28 (07) 3015-3022
- 72 de Pauli Paglioni M, Araújo ALD, Arboleda LPA. et al. Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities. A systematic review. Oral Oncol 2019; 93: 21-28
- 73 Hanna R, Dalvi S, Benedicenti S. et al. Photobiomodulation therapy in oral mucositis and potentially malignant oral lesions: a therapy towards the future. Cancers (Basel) 2020; 12 (07) E1949
- 74 de Faria CMG, Barrera-Patiño CP, Santana JPP, da Silva de Avó LR, Bagnato VS. Tumor radiosensitization by photobiomodulation. J Photochem Photobiol B 2021; 225: 112349
- 75 Robijns J, Censabella S, Claes S. et al. Prevention of acute radiodermatitis by photobiomodulation: a randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial). Lasers Surg Med 2018; 50 (07) 763-771
- 76 Zecha JA, Raber-Durlacher JE, Nair RG. et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer 2016; 24 (06) 2781-2792
- 77 Zecha JA, Raber-Durlacher JE, Nair RG. et al. Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Support Care Cancer 2016; 24 (06) 2793-2805
- 78 Campos TM, do Prado Tavares Silva CA, Sobral APT. et al. Photobiomodulation in oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis followed by a cost-effectiveness analysis. Support Care Cancer 2020; 28 (12) 5649-5659
- 79 Martins AFL, Morais MO, de Sousa-Neto SS. et al. Photobiomodulation reduces the impact of radiotherapy on oral health-related quality of life due to mucositis-related symptoms in head and neck cancer patients. Lasers Med Sci 2021; 36 (04) 903-912
- 80 Raggio BS, Winters R. Modern management of osteoradionecrosis. Curr Opin Otolaryngol Head Neck Surg 2018; 26 (04) 254-259
- 81 Rivero JA, Shamji O, Kolokythas A. Osteoradionecrosis: a review of pathophysiology, prevention and pharmacologic management using pentoxifylline, α-tocopherol, and clodronate. Oral Surg Oral Med Oral Pathol Oral Radiol 2017; 124 (05) 464-471
- 82 Martos-Fernández M, Saez-Barba M, López-López J, Estrugo-Devesa A, Balibrea-Del-Castillo JM, Bescós-Atín C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 125 (05) 431-439
- 83 Delanian S. Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol. Br J Radiol 1998; 71 (848) 892-894
- 84 Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003; 21 (13) 2545-2550
- 85 Delanian S, Lefaix JL. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 2004; 73 (02) 119-131
- 86 Delanian S, Lefaix JL. Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate. Br J Radiol 2002; 75 (893) 467-469
- 87 Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck 2005; 27 (02) 114-123
- 88 Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys 2011; 80 (03) 832-839
- 89 Hassan I, Dorjay K, Anwar P. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J 2014; 5 (04) 510-516
- 90 Vasconcelos AC, Berti-Couto SA, Azambuja AA. et al. Comparison of effects of clodronate and zoledronic acid on the repair of maxilla surgical wounds - histomorphometric, receptor activator of nuclear factor-kB ligand, osteoprotegerin, von Willebrand factor, and caspase-3 evaluation. J Oral Pathol Med 2012; 41 (09) 702-712
- 91 Sayed R, El Wakeel L, Saad AS, Kelany M, El-Hamamsy M. Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study. Med Oncol 2019; 37 (01) 8
- 92 Tocaciu S, Breik O. The need for more robust research on the role of pentoxifylline and tocopherol in the management of osteoradionecrosis of the jaws. Int J Oral Maxillofac Surg 2020; 49 (04) 544-545
- 93 Hayashi M, Pellecer M, Chung E, Sung E. The efficacy of pentoxifylline/tocopherol combination in the treatment of osteoradionecrosis. Spec Care Dentist 2015; 35 (06) 268-271
- 94 Patel V, Gadiwalla Y, Sassoon I, Sproat C, Kwok J, McGurk M. Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck. Br J Oral Maxillofac Surg 2016; 54 (05) 547-550
- 95 Rice N, Polyzois I, Ekanayake K, Omer O, Stassen LF. The management of osteoradionecrosis of the jaws–a review. Surgeon 2015; 13 (02) 101-109
- 96 Dinnoo A, Bidault F, Lassau N. et al. Long-term recurrences of jaw osteoradionecrosis after apparent healing with the PENTOCLO protocol. J Stomatol Oral Maxillofac Surg 2020; 121 (03) 286-287
- 97 Glicksman JT, Khalili S, Fung K, Parnes LS, Agrawal SK. Pentoxifylline-tocopherol-clodronate combination: a novel treatment for osteoradionecrosis of the temporal bone. Head Neck 2015; 37 (12) E191-E193
- 98 Haydont V, Bourgier C, Pocard M. et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007; 13 (18, Pt 1): 5331-5340
- 99 Jang H, Kwak SY, Park S. et al. Pravastatin alleviates radiation proctitis by regulating thrombomodulin in irradiated endothelial cells. Int J Mol Sci 2020; 21 (05) x
- 100 Holler V, Buard V, Gaugler MH. et al. Pravastatin limits radiation-induced vascular dysfunction in the skin. J Invest Dermatol 2009; 129 (05) 1280-1291
- 101 Bourgier C, Auperin A, Rivera S. et al. Pravastatin reverses established radiation-induced cutaneous and subcutaneous fibrosis in patients with head and neck cancer: results of the biology-driven phase 2 clinical trial PRAVACUR. Int J Radiat Oncol Biol Phys 2019; 104 (02) 365-373
- 102 Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?. Int J Radiat Oncol Biol Phys 2000; 47 (02) 277-290
- 103 Grossberg AJ, Lei X, Xu T. et al. Association of transforming growth factor beta polymorphism C-509T with radiation-induced fibrosis among patients with early-stage breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018; 4 (12) 1751-1757
- 104 Park JH, Ryu SH, Choi EK. et al. SKI2162, an inhibitor of the TGF-β type I receptor (ALK5), inhibits radiation-induced fibrosis in mice. Oncotarget 2015; 6 (06) 4171-4179
- 105 Dadrich M, Nicolay NH, Flechsig P. et al. Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis. OncoImmunology 2015; 5 (05) e1123366
- 106 Rice LM, Padilla CM, McLaughlin SR. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125 (07) 2795-2807
- 107 Formenti SC, Lee P, Adams S. et al. Focal irradiation and systemic TGFβ blockade in metastatic breast cancer. Clin Cancer Res 2018; 24 (11) 2493-2504
- 108 Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001; 97 (04) 1115-1122
- 109 Woo KJ, Lee TJ, Park JW, Kwon TK. Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway. Biochem Biophys Res Commun 2006; 343 (01) 8-14
- 110 Lavin CV, Abbas DB, Fahy EJ. et al. A comparative analysis of deferoxamine treatment modalities for dermal radiation-induced fibrosis. J Cell Mol Med 2021; 25 (21) 10028-10038
- 111 Shen AH, Borrelli MR, Adem S. et al. Prophylactic treatment with transdermal deferoxamine mitigates radiation-induced skin fibrosis. Sci Rep 2020; 10 (01) 12346
- 112 Mericli AF, Das A, Best R, Rodeheaver P, Rodeheaver G, Lin KY. Deferoxamine mitigates radiation-induced tissue injury in a rat irradiated TRAM flap model. Plast Reconstr Surg 2015; 135 (01) 124e-134e
- 113 Flacco J, Chung N, Blackshear CP. et al. Deferoxamine preconditioning of irradiated tissue improves perfusion and fat graft retention. Plast Reconstr Surg 2018; 141 (03) 655-665
- 114 Voest EE, Vreugdenhil G, Marx JJ. Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994; 120 (06) 490-499
- 115 Tevlin R, Longaker MT, Wan DC. Deferoxamine to minimize fibrosis during radiation therapy. Adv Wound Care (New Rochelle) 2021; (e-pub ahead of print)